Background: Giant-cell (temporal) arteritis is a systemic vasculitis affecting elderly people
that can lead to blindness. Current treatment involves at least 1 year of corticosteroid …

Objective To define the optimal corticosteroid dose regimen in the initial treatment of
temporal arteritis (TA). Methods We conducted a retrospective long-term evaluation of the …

More than half the patients with temporal arteritis experience steroid-related side effects,
which are associated with increased morbidity and may shorten life expectancy. We …

Introduction Although giant cell or temporal arteritis represents 5–10% of ischaemic optic
neuropathies and is the most common arteritis in people over 60 years old. Currently there is …

Opinion statement Corticosteroid treatment should start directly after suspected diagnosis.
The diagnosis should be confirmed within the next 5 days by histology or ultrasound …

High-dose corticosteroids (CS) are the mainstay of treatment for temporal (giant cell) arteritis
(TA). A usually required long-term treatment with CS, ranging from 1 to 5 years or more …

Objectives To analyze steroid related complications in patients with temporal arteritis (TA)
and to evaluate their possible effect on survival. Methods Forty-three consecutive patients …

INTRODUCTION: Although giant cell or temporal arteritis represents 5-10% of ischaemic
optic neuropathies and is the most common arteritis in people over 60 years old. Currently …

Preview Visual loss is the most common complication of temporal arteritis when the disease
is misdiagnosed or undertreated, yet treatment recommendations vary among different …

Temporal Arteritis 37 Page 453 Temporal Arteritis 37 Seth M. Kantor, MD KEY POINTS
Pretest Probabilities • Temporal arteritis usually occurs in persons older than 50 years old …